The opportunity.

With financial support from the ongoing capital injection, SeqCure estimates that clinical Proof-of-Concept can be reached within 4 years. Furthermore, regulatory pathways exist to support a fast- track clinical development program and approval process.

Based on data from clinical trials using autologous (derived from the same individual) tumor- infiltrating lymphocytes and the unprecedented tumor specificity of SeqCure^NEO, the product can be expected to be well tolerated compared to many other types of cancer treatment, including cell therapies involving genetic engineering.

Key competitive features of SeqCure^NEO include:

Highly individualized. The cell product is tailor-made from the mutation profile of each individual patient tumor.

Unprecedented level of control over tumor specificity, resulting in a cell product with high purity.The high purity enables delivery of the required dose to achieve a clinical response.

Whole blood (and not tumor tissue) is used as a source for the cell product, eliminating the need for additional surgical procedures.

SeqCure^NEO is nonengineered and targets multiple neoantigens, ensuring high safety in combination with a much broader tumor reactivity compared to other cell immunotherapy products.